A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 1,568,708 shares of CLDX stock, worth $39.4 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
1,568,708
Previous 1,937,991 19.05%
Holding current value
$39.4 Million
Previous $71.7 Million 25.7%
% of portfolio
0.15%
Previous 0.2%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$32.06 - $44.56 $11.8 Million - $16.5 Million
-369,283 Reduced 19.05%
1,568,708 $53.3 Million
Q2 2024

Aug 14, 2024

BUY
$32.76 - $42.56 $21.4 Million - $27.8 Million
654,194 Added 50.96%
1,937,991 $71.7 Million
Q1 2024

May 15, 2024

SELL
$35.22 - $51.88 $51.9 Million - $76.4 Million
-1,472,325 Reduced 53.42%
1,283,797 $53.9 Million
Q4 2023

Feb 14, 2024

BUY
$22.61 - $40.65 $32 Million - $57.5 Million
1,413,722 Added 105.31%
2,756,122 $109 Million
Q3 2023

Nov 14, 2023

BUY
$25.45 - $37.46 $4.01 Million - $5.9 Million
157,600 Added 13.3%
1,342,400 $36.9 Million
Q2 2023

Aug 14, 2023

BUY
$30.29 - $38.28 $28.9 Million - $36.6 Million
955,297 Added 416.25%
1,184,800 $40.2 Million
Q1 2023

May 15, 2023

SELL
$34.78 - $47.43 $9.61 Million - $13.1 Million
-276,297 Reduced 54.63%
229,503 $8.26 Million
Q4 2022

Feb 14, 2023

BUY
$27.78 - $45.38 $10.3 Million - $16.8 Million
370,800 Added 274.67%
505,800 $22.5 Million
Q3 2022

Nov 14, 2022

BUY
$22.7 - $37.57 $3.06 Million - $5.07 Million
135,000 New
135,000 $3.8 Million
Q2 2021

Aug 16, 2021

SELL
$20.71 - $35.37 $954,731 - $1.63 Million
-46,100 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$16.19 - $29.91 $746,359 - $1.38 Million
46,100 New
46,100 $950,000

Others Institutions Holding CLDX

About Celldex Therapeutics, Inc.


  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $1.18B
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.